Olanzapine and haloperidol for residual symptoms.
Lieuwe
L
de Haan
Nico
N
van Beveren
D000553:Ambulatory Care; D014150:Antipsychotic Agents / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000627:therapeutic use*; D001569:Benzodiazepines / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000627:therapeutic use*; D004305:Dose-Response Relationship, Drug; D006220:Haloperidol / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000627:therapeutic use*; D006801:Humans; D000077152:Olanzapine; D017448:Receptors, Dopamine D2 / Q000378:metabolism; D012107:Research Design / Q000592:standards; D012559:Schizophrenia / Q000188:drug therapy*; D012565:Schizophrenic Psychology; D016896:Treatment Outcome
D014150:Antipsychotic Agents; D017448:Receptors, Dopamine D2; D001569:Benzodiazepines; D006220:Haloperidol; D000077152:Olanzapine